on Eckert & Ziegler Strahlen- Und Medizintechnik AG (ETR:EUZ)
Berenberg Initiates 'Buy' Rating for Eckert & Ziegler with Significant Upside
Eckert & Ziegler SE, a prominent player in the isotope technology segment for nuclear medicine, has received a favorable evaluation from Joh. Berenberg, Gossler & Co. KG. The Hamburg private bank's analysts have started coverage with a "Buy" recommendation and set a price target of €24. This indicates a potential price increase of 46.8% from the Xetra closing price of €16.35 on September 8, 2025.
The analysis highlights the firm's strong market presence, driven by growing demand for radioisotopes in nuclear medicine diagnostics and therapy. Eckert & Ziegler's offerings in the radiopharmaceutical sector are expected to maintain their importance amidst these market trends.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Eckert & Ziegler Strahlen- Und Medizintechnik AG news